Neopharm Group
Kobby Finkelstein has held various roles in the finance industry. Kobby started their career in 1998 as a Fund Manager at Dikla Mutual Funds (FIBI) and later moved to Moritz-Tuchler as a Fund Manager in 2000. In 2001, they joined Investec (Israel) as an Analyst, Head of Research, and Head of Derivatives Advisory & Underwriting. In 2004, they became the Head of International Investments at Meitav Dash - Provident and Pension Funds, where they worked until 2014. Since 2014, Kobby has been serving as the Chief Investment Officer at Neopharm Group.
Kobby Finkelstein has a strong education background in the field of finance and economics. Kobby attended Bar-Ilan University from 1991 to 1994, where they earned a Bachelor of Arts degree in Economics with Magna Cum Laude honors. Later, from 1994 to 1997, they pursued a Master of Business Administration degree in Finance at the same institution, again achieving Magna Cum Laude honors. In 2007, Kobby Finkelstein furthered their education by attending the CFA Institute, where they completed the Chartered Financial Analyst program from 2007 to 2009.
This person is not in any offices
Neopharm Group
Neopharm Group is engaged in research and development, manufacturing, marketing, sales and distribution of a broad range of products in the health care field in 60 countries globally. Founded in 1941, over 900 employees worldwide, offices in Israel, Europe, U.S. and the Middle East and annual revenues exceeding $US400 million Our family of companies operate in five major segments: The Pharmaceutical segment - "Neopharm Israel" provides innovative solutions for improving health in the fields of oncology, hematology, infectious or autoimmune diseases, metabolic diseases, neurology, gastroenterology and dermatology. Also provides medical care to patients in the comfort of their own home as an alternative to hospitalization also Imports drugs that are unregistered in Israel with a permit of the Ministry of Health and imports generic products. "Neovi" Swiss-based global biopharmaceutical company developing and bringing to market novel antibody therapies in transplantation medicine, oncology and immune disorders. The Medical segment - "Eldan" is dedicated to the marketing, sales and technical service of equipment, instrumentation and consumables in the areas of healthcare and life science The Consumer Healthcare segment - "Neopharm consumer products" offers wellness and healthcare products via our in-house development and manufacturing capabilities and via partnering with world's leading Consumer Healthcare companies. Operates in the areas of infant nutrition, wet-wipes, diapers, personal and skin care, multivitamins and over the counter medicines The Supply Chain segment - "Promedico" offers operational services and supply chain. The Environmental segment -"L.D.D" is dedicated to the treatment and rehabilitation of contaminated soil and water For all Jobs: https://www.neopharmgroup.com/careers/new/public/?ref=group_website&utm_source=neopharmgroup_website